Allergic Broncho-Pulmonary Aspergillosis Clinical Trial
Official title:
Interest of TARC Serum Marker for Follow-up of Patients With Allergic Broncho-Pulmonary Aspergillosis (ABPA), Excluding Cystic Fibrosis
The main objective of this study is to determine if a doubling of serum TARC (compared to
baseline) is associated with the occurrence of exacerbations of ABPA.
The secondary objectives of the study are :
1. To investigate if induced sputum eosinophils count (compared to baseline) is associated
with the occurrence of exacerbations.
2. To examine if the exhaled NO (compared to a baseline) is associated with the occurrence
of exacerbations.
3. To investigate if activation of circulating T cells (compared to a baseline) is
associated with the occurrence of exacerbations.
4. To examine if the rate of specific Asp f IgG measured by ELISA (compared to a baseline)
is associated with the occurrence of exacerbations.
5. To determine if the variation of one of the markers above, TARC or Asp f specific IgE
measured at baseline, may be associated with the radiological stage of the disease
(ABPA-S, ABPA-CB, ABPA-ORF).
6. To investigate if there is a link between fungal exposure at home (visually assessed by
the contamination level and the proportion of positive samples for Asp. f) and the
frequency of exacerbations.
7. To establish if some of the clinical, functional or biological data studied are
associated with the frequency of exacerbations.
n/a